Risk Factors for Progression from Cytomegalovirus Viremia to Cytomegalovirus Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Ji Eun Jang, Shin Young Hyun, Yun Deok Kim, Sul Hee Yoon, Doh Yu Hwang, Soo Jeong Kim, Yuri Kim, Jin Seok Kim, June Won Cheong, Yoo Hong Min

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Cytomegalovirus (CMV) disease is a major cause of infectious complications in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although patients undergoing allo-HSCT receive prophylactic and preemptive treatment for CMV, a subset of patients experience clinically significant CMV disease. This study investigated the risk factors for progression from CMV viremia to CMV disease during or after preemptive therapy in patients undergoing allo-HSCT. Between January 2006 and August 2010, 43 patients received preemptive therapy for CMV viremia after allo-HSCT. These patients experienced 74 episodes of CMV viremia. Nine of the patients (21%) and 12 of the episodes (16%) progressed to CMV disease. Univariate analysis identified several risk factors for progression to CMV disease, including high initial viral load (. P = .020), leukopenia (. P = .012), and neutropenia (. P = .033) at the time of detection of CMV viremia. On multivariate analysis, leukopenia remained an independent predictor (hazard ratio, 4.347; . P = .045). The rate of failure to clear CMV viremia after 1 cycle of preemptive therapy was higher in the leukopenia group than in the non-leukopenia group (60.0% versus 16.9%; . P = .002). This indicates that leukopenia initially documented with CMV viremia is related to lower viral response to preemptive therapy and is a notable risk factor for progression from CMV viremia to CMV disease.

Original languageEnglish
Pages (from-to)881-886
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume18
Issue number6
DOIs
Publication statusPublished - 2012 Jun 1

Fingerprint

Viremia
Hematopoietic Stem Cell Transplantation
Cytomegalovirus
Leukopenia
Therapeutics
Neutropenia
Viral Load

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Jang, Ji Eun ; Hyun, Shin Young ; Kim, Yun Deok ; Yoon, Sul Hee ; Hwang, Doh Yu ; Kim, Soo Jeong ; Kim, Yuri ; Kim, Jin Seok ; Cheong, June Won ; Min, Yoo Hong. / Risk Factors for Progression from Cytomegalovirus Viremia to Cytomegalovirus Disease after Allogeneic Hematopoietic Stem Cell Transplantation. In: Biology of Blood and Marrow Transplantation. 2012 ; Vol. 18, No. 6. pp. 881-886.
@article{69d6c9840cf944c0b9550237c7a47cbe,
title = "Risk Factors for Progression from Cytomegalovirus Viremia to Cytomegalovirus Disease after Allogeneic Hematopoietic Stem Cell Transplantation",
abstract = "Cytomegalovirus (CMV) disease is a major cause of infectious complications in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although patients undergoing allo-HSCT receive prophylactic and preemptive treatment for CMV, a subset of patients experience clinically significant CMV disease. This study investigated the risk factors for progression from CMV viremia to CMV disease during or after preemptive therapy in patients undergoing allo-HSCT. Between January 2006 and August 2010, 43 patients received preemptive therapy for CMV viremia after allo-HSCT. These patients experienced 74 episodes of CMV viremia. Nine of the patients (21{\%}) and 12 of the episodes (16{\%}) progressed to CMV disease. Univariate analysis identified several risk factors for progression to CMV disease, including high initial viral load (. P = .020), leukopenia (. P = .012), and neutropenia (. P = .033) at the time of detection of CMV viremia. On multivariate analysis, leukopenia remained an independent predictor (hazard ratio, 4.347; . P = .045). The rate of failure to clear CMV viremia after 1 cycle of preemptive therapy was higher in the leukopenia group than in the non-leukopenia group (60.0{\%} versus 16.9{\%}; . P = .002). This indicates that leukopenia initially documented with CMV viremia is related to lower viral response to preemptive therapy and is a notable risk factor for progression from CMV viremia to CMV disease.",
author = "Jang, {Ji Eun} and Hyun, {Shin Young} and Kim, {Yun Deok} and Yoon, {Sul Hee} and Hwang, {Doh Yu} and Kim, {Soo Jeong} and Yuri Kim and Kim, {Jin Seok} and Cheong, {June Won} and Min, {Yoo Hong}",
year = "2012",
month = "6",
day = "1",
doi = "10.1016/j.bbmt.2011.10.037",
language = "English",
volume = "18",
pages = "881--886",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "6",

}

Risk Factors for Progression from Cytomegalovirus Viremia to Cytomegalovirus Disease after Allogeneic Hematopoietic Stem Cell Transplantation. / Jang, Ji Eun; Hyun, Shin Young; Kim, Yun Deok; Yoon, Sul Hee; Hwang, Doh Yu; Kim, Soo Jeong; Kim, Yuri; Kim, Jin Seok; Cheong, June Won; Min, Yoo Hong.

In: Biology of Blood and Marrow Transplantation, Vol. 18, No. 6, 01.06.2012, p. 881-886.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Risk Factors for Progression from Cytomegalovirus Viremia to Cytomegalovirus Disease after Allogeneic Hematopoietic Stem Cell Transplantation

AU - Jang, Ji Eun

AU - Hyun, Shin Young

AU - Kim, Yun Deok

AU - Yoon, Sul Hee

AU - Hwang, Doh Yu

AU - Kim, Soo Jeong

AU - Kim, Yuri

AU - Kim, Jin Seok

AU - Cheong, June Won

AU - Min, Yoo Hong

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Cytomegalovirus (CMV) disease is a major cause of infectious complications in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although patients undergoing allo-HSCT receive prophylactic and preemptive treatment for CMV, a subset of patients experience clinically significant CMV disease. This study investigated the risk factors for progression from CMV viremia to CMV disease during or after preemptive therapy in patients undergoing allo-HSCT. Between January 2006 and August 2010, 43 patients received preemptive therapy for CMV viremia after allo-HSCT. These patients experienced 74 episodes of CMV viremia. Nine of the patients (21%) and 12 of the episodes (16%) progressed to CMV disease. Univariate analysis identified several risk factors for progression to CMV disease, including high initial viral load (. P = .020), leukopenia (. P = .012), and neutropenia (. P = .033) at the time of detection of CMV viremia. On multivariate analysis, leukopenia remained an independent predictor (hazard ratio, 4.347; . P = .045). The rate of failure to clear CMV viremia after 1 cycle of preemptive therapy was higher in the leukopenia group than in the non-leukopenia group (60.0% versus 16.9%; . P = .002). This indicates that leukopenia initially documented with CMV viremia is related to lower viral response to preemptive therapy and is a notable risk factor for progression from CMV viremia to CMV disease.

AB - Cytomegalovirus (CMV) disease is a major cause of infectious complications in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although patients undergoing allo-HSCT receive prophylactic and preemptive treatment for CMV, a subset of patients experience clinically significant CMV disease. This study investigated the risk factors for progression from CMV viremia to CMV disease during or after preemptive therapy in patients undergoing allo-HSCT. Between January 2006 and August 2010, 43 patients received preemptive therapy for CMV viremia after allo-HSCT. These patients experienced 74 episodes of CMV viremia. Nine of the patients (21%) and 12 of the episodes (16%) progressed to CMV disease. Univariate analysis identified several risk factors for progression to CMV disease, including high initial viral load (. P = .020), leukopenia (. P = .012), and neutropenia (. P = .033) at the time of detection of CMV viremia. On multivariate analysis, leukopenia remained an independent predictor (hazard ratio, 4.347; . P = .045). The rate of failure to clear CMV viremia after 1 cycle of preemptive therapy was higher in the leukopenia group than in the non-leukopenia group (60.0% versus 16.9%; . P = .002). This indicates that leukopenia initially documented with CMV viremia is related to lower viral response to preemptive therapy and is a notable risk factor for progression from CMV viremia to CMV disease.

UR - http://www.scopus.com/inward/record.url?scp=84860839178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860839178&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2011.10.037

DO - 10.1016/j.bbmt.2011.10.037

M3 - Article

C2 - 22062802

AN - SCOPUS:84860839178

VL - 18

SP - 881

EP - 886

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 6

ER -